Doheny Eye Institute

Organization Overview

Doheny Eye Institute is located in Pasadena, CA. The organization was established in 1973. According to its NTEE Classification (G41) the organization is classified as: Eye Diseases, Blindness & Vision Impairments, under the broad grouping of Voluntary Health Associations & Medical Disciplines and related organizations. As of 06/2023, Doheny Eye Institute employed 147 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Doheny Eye Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.

For the year ending 06/2023, Doheny Eye Institute generated $25.5m in total revenue. This represents relatively stable growth, over the past 8 years the organization has increased revenue by an average of 1.8% each year. All expenses for the organization totaled $22.6m during the year ending 06/2023. While expenses have increased by 0.3% per year over the past 8 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.

Mission & Program ActivityExcerpts From the 990T Filing

TAX YEAR

2023

Describe the Organization's Mission:

Part 3 - Line 1

TO FURTHER THE CONSERVATION, IMPROVEMENT AND RESTORATION OF HUMAN EYESIGHT.

Describe the Organization's Program Activity:

THE MISSION OF THE DOHENY EYE INSTITUTE (DEI), TO FURTHER THE CONSERVATION, IMPROVEMENT AND RESTORATION OF HUMAN EYESIGHT, IS GUIDED BY THE FOLLOWING OBJECTIVES: 1. TO INCREASE KNOWLEDGE OF THE HUMAN EYE, ITS CONDITIONS AND DISEASES, THROUGH RESEARCH; 2. TO TRANSMIT THIS KNOWLEDGE THROUGH EDUCATION, TRAINING, AND COMMUNITY SERVICE; AND 3. TO FACILITATE THE APPLICATION OF ITS RESEARCH TO IMPROVE PATIENT CARE AND FOSTER FURTHER RESEARCH. RESEARCH ACTIVITIES FOR THE PERIOD AND SELECTED FOR LONG-TERM FOCUS INCLUDE: RETINAL AND MACULAR DEGENERATION RESEARCH THROUGH THE STUDY OF RETINAL PIGMENT EPITHELIUM AND THE USE OF ADVANCED RETINAL IMAGING IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD) AND IMAGE ANALYSIS USING ARTIFICIAL INTELLEGENCE; MOLECULAR GENETICS OF INHERITED DISEASE OF THE RETINA AND GENE THERAPY FOR RETINAL DISORDERS; INVESTIGATIONS OF RETINAL VASCULAR STIFFNESS AS A POTENTIAL CAUSATIVE FACTOR IN DIABETIC RETINOPATHY AND AMD; RESEARCH FOCUSED ON DEFINING THE MOLECULAR DETAILS LINKING MITOCHONDRIAL DYSFUNCTION AND ALTERED SIGNALING BETWEEN RETINAL NEURONS. ON DECEMBER 18, 2013, THE DOHENY EYE INSTITUTE EXECUTED AN AGREEMENT WITH THE UNIVERSITY OF CALIFORNIA AT LOS ANGELES (UCLA) FOR A 99 YEAR AFFILIATION. THE PURPOSE OF THIS AFFILIATION IS TO CARRY OUT THE INSTITUTE'S MISSION -- TO FURTHER THE CONSERVATION, IMPROVEMENT, AND RESTORATION OF HUMAN EYESIGHT -- THROUGH RESEARCH, EDUCATION, AND CLINICAL CARE (CLINICAL CARE IS PROVIDED DIRECTLY BY UCLA). BOTH THE INSTITUTE AND UCLA-STEIN EYE INSTITUTE ARE DEDICATED TO PROVIDING THE PUBLIC WITH THE HIGHEST QUALITY OF OPHTHALMIC CARE AND THE MOST INNOVATIVE AND STRATEGIC RESEARCH FOR THE IMPROVEMENT OF HUMAN EYESIGHT. IN NOV. 2021 DOHENY EYE INSTITUTE (DEI) MOVED TO ITS NEW LOCATION - 150 ORANGE GROVE BLVD IN PASADENA, CA. NEW AREAS OF RESEARCH DEI IS STUDYING THE MECHANISMS RESPONSIBLE FOR DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION (AMD), THE NUMBER ONE CAUSE OF BLINDNESS AMONG INDIVIDUALS OVER 60 YEARS OLD IN THE USA. THE RISK OF DEVELOPING AMD IS SIGNIFICANTLY INCREASED WHEN SPECIFIC GENES ARE MUTATED. ONE NEW STUDY IS FOCUSED ON STUDYING THE RETINAL CELLS IN THE POPULATION OF PATIENTS HARBORING A SPECIFIC MUTATION IN A GENE INVOLVED IN THE IMMUNE SYSTEM. A SECOND STUDY IS FOCUSED ON A DIFFERENT GENE OF UNKNOWN FUNCTION BUT WITH HIGH IMPACT ON AMD. THE RESEARCHERS ARE STUDYING RETINAL CELLS GENERATED FROM AMD PATIENTS THAT HAVE THESE GENETIC DEFECTS. INFORMATION FROM THESE TWO STUDIES IS CRITICAL FOR DEVELOPMENT OF NEW THERAPIES FOR AMD THAT TARGET WHAT IS CAUSING THE DISEASE. IN OTHER STUDIES, DEI SCIENTISTS HAVE BEEN INVOLVED IN DEVELOPING NEW AND FASTER WAYS TO INTERPRET RETINAL IMAGES IN HUMAN PATIENTS USING ARTIFICIAL INTELLIGENCE (AI). IN TWO DIFFERENT STUDIES, AI-BASED APPROACHES FOR AUTOMATED INTERPRETATION OF IMAGES FROM PATIENTS WITH STARGARDT ATROPHY INCORPORATE INFORMATION FROM MULTIPLE IMAGING MODALITIES. ADDITIONALLY, BY FOLLOWING PATIENT IMAGES OVER TIME, AN AI-BASED AUTOMATED ALGORITHM IS BEING DEVELOPED TO PREDICT THE DEVELOPMENT AND PROGRESSION OF ATROPHY OVER TIME. DEI HAS DEVELOPED CUTTING EDGE IMAGING TECHNOLOGY, INCLUDING A NOVEL ADAPTIVE OPTICS NEAR-CONFOCAL OPHTHALMOSCOPE (AONCO) THAT ENABLES PRECISE EVALUATION OF THE DYNAMIC MOVEMENT OF ERYTHROCYTES WITHIN RETINAL CAPILLARIES, REFERRED TO AS "HIGHER-ORDER DYNAMICS". BY MONITORING ERYTHROCYTE VELOCITY WITHIN A CARDIAC CYCLE, THEY WILL VALIDATE THAT HIGHER ORDER HEMODYNAMICS IN RETINAL CAPILLARIES RESEMBLE THOSE CREATED FOR ASSESSING THE ARTERIAL STIFFNESS IN THE MACROVASCULAR SYSTEM. THIS WORK IS IMPORTANT BECAUSE WE WILL GAIN A BETTER UNDERSTANDING OF THE BLOOD FLOW OSCILLATIONS IN NORMAL HUMAN RETINAL CAPILLARIES AND DEVELOP NEW BIOMARKERS FOR DETECTING AGE- AND DISEASE-RELATED CHANGES IN THE RETINAL MICROCIRCULATION. DEI HAS ALSO DEVELOPED A PIONEERING ADAPTIVE OPTICS IMAGING INSTRUMENT THAT INTEGRATES SCANNING LASER OPHTHALMOSCOPY AND OPTICAL COHERENCE TOMOGRAPHY (AO-SLO-OCT). THIS INSTRUMENT CAN IMAGE THE RETINA WITH A 3-D SPATIAL RESOLUTION, ALLOWING FOR IN-VIVO ULTRASTRUCTURE ASSESSMENT OF INDIVIDUAL PHOTORECEPTORS IN BOTH EN FACE AND CROSS-SECTIONAL PLANES. THE IMPORTANCE IS THAT THIS ADAPTIVE OPTICS IMAGING OVERCOMES THE LIMITATIONS PRESENTED BY OPTICAL DEFECTS IN LIVING EYES, ALLOWING FOR HIGH RESOLUTION IMAGES OF NOT ONLY PHOTORECEPTORS, BUT ALSO THE CHORIOCAPILLARIS IN THE STUDY OF VARIOUS CHORIORETINAL DISEASES, INCLUDING AMD. ANOTHER IMAGING TECHNIQUE USED BY DEI SCIENTISTS IS THE USE OF CALCIUM IMAGING IN CONJUNCTION WITH CONFOCAL MICROSCOPY TO CHARACTERIZE THE EFFECTS OF OXIDATIVE STRESS ON THE RETINAL GANGLION CELLS. THESE EXPERIMENTS WILL IDENTIFY THE EARLY DEFICITS IN GANGLION CELL ELECTROPHYSIOLOGICAL FUNCTION RESULTING FROM MITOCHONDRIAL DYSFUNCTION. BY CAREFULLY ANALYZING THE EARLIEST SIGNS OF CHANGES TO PHOTORECEPTOR RESPONSE AND SYNAPTIC OUTPUT TO BIPOLAR CELLS, THIS DETECTION AND INTERPRETATION COULD LEAD TO DIAGNOSTIC CLUES THAT AID DETECTION OF PERSONS AT HIGHER RISK OF GLAUCOMA OR OPTIC NEUROPATHY. AN ADDITIONAL NEW AREA INVOLVES INVESTIGATIONS OF THE EARLY STAGES OF INFLAMMATION-MEDIATED DEGENERATION OF BLOOD VESSELS, FOCUSING ON THE ATROPHY OF INNER RETINAL VESSELS IN DIABETIC RETINOPATHY AND THE OUTER RETINAL BLOOD SUPPLY FROM THE CHORIOCAPILLARIS/CHOROID IN AMD. THIS INTEGRATION OF THE PRINCIPLES OF VASCULAR BIOLOGY, INFLAMMATION, AND MECHANOBIOLOGY, HAS LED TO A UNIQUE INTERDISCIPLINARY APPROACH THAT HAS THE POTENTIAL TO IDENTIFY CONTRIBUTIONS OF ALTERED VASCULAR STIFFNESS AS A PREVIOUSLY UNRECOGNIZED MECHANISM UNDERLYING THE PATHOGENESIS OF THESE PREVALENT OCULAR DISEASES.


Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.

Outside Vendors & Contractors

Vendor Name (Service)Compensation
Maginnis Knechtel And Mcintyre Llp
Audit And Tax
$184,500
Lindon Law Corporation
Legal
$128,830
View All Vendors

Financial Statements

Statement of Revenue
Federated campaigns$0
Membership dues$0
Fundraising events$0
Related organizations$0
Government grants $3,090,948
All other contributions, gifts, grants, and similar amounts not included above$2,141,140
Noncash contributions included in lines 1a–1f $0
Total Revenue from Contributions, Gifts, Grants & Similar$5,232,088
Total Program Service Revenue$5,447,881
Investment income $1,510,442
Tax Exempt Bond Proceeds $0
Royalties $11,759
Net Rental Income $0
Net Gain/Loss on Asset Sales $12,807,006
Net Income from Fundraising Events $0
Net Income from Gaming Activities $0
Net Income from Sales of Inventory $0
Miscellaneous Revenue$0
Total Revenue $25,491,176

Peer Organizations

Organization NameAssets
Doheny Eye Institute
Pasadena, CA
$25,491,176
Foundation For Blind Children
Phoenix, AZ
$11,160,600
Saavi Services For The Blind
Tucson, AZ
$6,156,877
Association Of University Professors Of Ophthalmology Inc
San Francisco, CA
$4,834,057
Restoringvision
San Francisco, CA
$3,676,482
Vista Center For The Blind And Visually Impaired
Palo Alto, CA
$3,227,087
California Optometric Association
Sacramento, CA
$4,432,915
The Armenian Eyecare Project
San Dimas, CA
$1,726,364
Society For The Blind
Sacramento, CA
$3,159,291
International Council Of Ophthalmology Foundation
San Francisco, CA
$270,113
Oregon Lions Sight And Hearing Foundation Inc
Portland, OR
$1,778,141
American Glaucome Society Inc
San Francisco, CA
$2,502,848
Arizona Center For The Blind And Visually Impaired
Phoenix, AZ
$2,992,075
San Diego Center For The Blind
San Diego, CA
$1,394,641
Women In Ophthalmology Inc
San Francisco, CA
$1,955,217
Valley Center For The Blind
Fresno, CA
$1,558,998
Loma Linda Univeristy Eye Medical Group Inc
Loma Linda, CA
$0
Blind & Visually Impaired Center Of Monterey County Inc
Pacific Grove, CA
$676,783
Arizona Optometric Association Inc
Scottsdale, AZ
$934,936
Lions Eye Foundation Of California Nevada Inc
San Francisco, CA
$1,092,109
Lions Sight And Hearing Foundation Of Southern California
Long Beach, CA
$126,815
Clear Vision Foundation
Eugene, OR
$892,700
Community Center For The Blind And Visually Impaired
Stockton, CA
$487,386
Arizona Lions Vision And Hearing Foundation Of Multiple District 21
Phoenix, AZ
$420,112
Lions Center For The Visually Impaired Inc
Pittsburg, CA
$864,827

Create an account to unlock the data you need.

or